

APPENDICES 3Y

PainChek® Ltd (ASX: PCK) (“PainChek®” or “the Company”) attaches updated Appendices 3Y for each of the Company’s directors.

PainChek has recently conducted a review of notifications provided to ASX with respect to securities on issue. It has come to light that securities were issued, cancelled or converted during 2022 which have not been notified to ASX due to an administrative oversight. As a result, directors’ interests in shares were impacted and the attached Appendices 3Y are being lodged outside the timeframe prescribed by ASX Listing Rule 3.19A.2.

The market has been informed of all new issues of securities to directors; directors’ participation in the entitlement offer was disclosed to the market on 4 July 2022, the terms of all Performance Rights issued to the directors have been disclosed and all Performance Rights allotted to directors have received prior shareholder approval.

The Company is aware of its disclosure obligations under ASX Listing Rules 3.19A, 3.19B and 3.10 and has now reviewed and amended its reporting and notification practices. The Company believes that the new arrangements are adequate to ensure compliance with its disclosure obligations under the ASX Listing Rules.

The directors are requested to declare any interests and note any changes to their interests at each Board meeting. Further, the Company’s Securities Trading Policy sets out the appropriate notifications pertaining to relevant interests that directors are obliged to provide to the Company. All directors have been made aware of the contents and application of the Securities Trading Policy.

This release has been authorised for release by the Board of Directors.

For more information:

Lisa Dadswell
Company Secretary, PainChek
lisa.dadswell@boardroomlimited.com.au
02 8016 2819

Philip Daffas
CEO, PainChek
philip.daffas@painchek.com
0406 537 235

About PainChek®

PainChek® Ltd is an Australian based company that develops pain assessment technologies.

Pain often goes unrecognised and under-treated in people with communication difficulties. PainChek Universal is a clinically validated smartphone-based medical device that enables best practice pain assessment for all people, everywhere.

PainChek Universal is a complete point-of-care solution that combines the existing PainChek® App with the Numerical Rating Scale (NRS). This enables best-practice pain management for all residents living with pain in any environment — from those who cannot verbalise pain to those who can, and those who fluctuate between the two.

The PainChek® App uses artificial intelligence and facial recognition to detect pain in those who cannot self-report. This gives a voice to those who cannot verbalise pain, whilst also driving objectivity and consistency in all assessments. For those who can self-report, PainChek Universal also includes access to the Numerical Rating Scale, a well-established standard used to document pain levels amongst these individuals. PainChek Universal also supports pain assessment using both tools at the point of care, for those people whose ability to communicate fluctuates.

PainChek® is being rolled out globally in two phases: first, PainChek® for adults who are unable to effectively verbalise their pain such as people with dementia, and second, PainChek® for infants who have not yet learnt to speak. Both the adult and infants products have received regulatory clearance in numerous markets including Australia, Europe, UK, NZ, Singapore and Canada.

The PainChek® Shared Care Program is a PainChek® licensing model which enables a professional carer to share their resident or patient data securely with other healthcare professionals or designated homebased family carers for ongoing pain assessments or clinical data review.

To find out more, visit www.painchek.com

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	PainChek Limited
ABN	21 146 035 127

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Adam Davey
Date of last notice	16 September 2021

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct & Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Adam Davey as Trustee for the Shenton Park Investment Trust (Trustee & Beneficiary)
Date of change	Various – see below
No. of securities held prior to change	<ol style="list-style-type: none"> 1. 6,149,874 Ordinary Shares (Indirect) 2. 3,840,487* Ordinary Shares (Direct) 3. 396,040* Performance Rights (Direct)
Class	Ordinary Shares & Performance Rights
Number acquired	<ol style="list-style-type: none"> 1. Ordinary Shares – Indirect <ol style="list-style-type: none"> a. 3,540,764 on 29/3/2022 b. 484,532 on 3/8/2022 2. Ordinary Shares – Direct <ol style="list-style-type: none"> a. 396,040 on 13/7/2022 b. 14,987 on 3/8/2022 3. Performance Rights – Direct <ol style="list-style-type: none"> a. 675,676 on 13/2/2023

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Number disposed	<p>2. Ordinary Shares – Direct c. 3,540,764 on 29/3/2022</p> <p>3. Performance Rights – Direct b. 396,040 on 13/7/2022</p>
<p>Value/Consideration includes brokerage/gst Note: If consideration is non-cash, provide details and estimated valuation</p>	<p>1(a) – N/A – Transfer from direct account to indirect account 1(b) – \$13,567</p> <p>2(a) - Nil consideration - conversion of Performance Rights into Shares. Est. value \$11,881 2(b) - \$417 2(c) – Refer 1(a) above</p> <p>3(a) - Nil consideration - allotment of Performance Rights. Est. value \$18,243 3(b) – Refer 2(a) above</p>
No. of securities held after change	<p>1. 10,175,170 Ordinary Shares (Indirect) 2. 710,750 Ordinary Shares (Direct) 3. 675,676 Performance Rights (Direct)</p>
<p>Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	<p>1(a) - Transfer from direct account to indirect account 1(b) - Acquisition under non-renounceable entitlement offer</p> <p>2(a) - Conversion of Performance Rights into Ordinary Shares 2(b) - Acquisition under non-renounceable entitlement offer 2(c) – Refer 1(a) above</p> <p>3(a) - Allotment of Performance Rights approved by Shareholders at 2022 AGM 3(b) – Refer 2(a) above</p>

** There was an error on the Appendix 3Y lodged on 16/9/2021 as the numbers of Ordinary Shares and Performance Rights failed to include 206,396 Performance Rights which had been converted into Ordinary Shares on 14/7/2021.*

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	PainChek Limited
ABN	21 146 035 127

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Cynthia Payne
Date of last notice	30 March 2022

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	
Date of change	13 February 2023
No. of securities held prior to change	Nil
Class	Performance Rights
Number acquired	675,676
Number disposed	
Value/Consideration includes brokerage/gst <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Allotment of Performance Rights. Est. value \$18,243

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held after change	675,676 Performance Rights
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Allotment of Performance Rights approved by Shareholders at 2022 AGM

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	PainChek Limited
ABN	21 146 035 127

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	John Murray
Date of last notice	16 September 2021

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct & Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Nanjop Pty Ltd (as Trustee for the Murring Family Trust) (Director & Beneficiary)
Date of change	Various – see below
No. of securities held prior to change	<ol style="list-style-type: none"> 1. 12,299,748 Ordinary Shares (Indirect) 2. 599,445* Ordinary Shares (Direct) 3. 792,079* Performance Rights (Direct)
Class	Ordinary Shares & Performance Rights
Number acquired	<ol style="list-style-type: none"> 1. Ordinary Shares - Indirect <ol style="list-style-type: none"> a) 614,987 Ordinary Shares on 3/8/2022 2. Ordinary Shares - Direct <ol style="list-style-type: none"> a) 792,079 on 13/7/2022 b) 29,972 on 3/8/2022 3. Performance Rights - Direct <ol style="list-style-type: none"> a) 1,351,351 on 13/2/2023
Number disposed	<ol style="list-style-type: none"> 3. Performance Rights - Direct <ol style="list-style-type: none"> b) 792,079 on 13/7/2022

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

<p>Value/Consideration includes brokerage/gst <small>Note: If consideration is non-cash, provide details and estimated valuation</small></p>	<p>1(a) - \$17,220</p> <p>2(a) - Nil consideration - conversion of Performance Rights into Shares. Est. value \$21,386</p> <p>2(b) - \$839</p> <p>3(a) - Nil consideration - allotment of Performance Rights. Est. value \$36,486</p> <p>3(b) – refer 2(a) above</p>
<p>No. of securities held after change</p>	<p>1. 12,914,735 Ordinary Shares (Indirect)</p> <p>2. 1,421,496 Ordinary Shares (Direct)</p> <p>3. 1,351,351 Performance Rights (Direct)</p>
<p>Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small></p>	<p>1(a) – Acquisition under non-renounceable entitlement offer</p> <p>2(a) - Conversion of Performance Rights into Ordinary Shares</p> <p>2(b) - Acquisition under non-renounceable entitlement offer</p> <p>(3)(a) Allotment of Performance Rights approved by Shareholders at 2022 AGM</p> <p>3(b) – refer 2(a) above</p>

** There was an error on the Appendix 3Y lodged on 16/9/2021 as the numbers of Ordinary Shares and Performance Rights failed to include 412,791 Performance Rights which had been converted into Ordinary Shares on 14/7/2021.*

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	No
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
<p>No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small></p>	N/A
Interest acquired	N/A
Interest disposed	N/A
<p>Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small></p>	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	PainChek Limited
ABN	21 146 035 127

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Philip Daffas
Date of last notice	16 September 2021

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	
Date of change	Various – see below
No. of securities held prior to change	(1) 20,499,581 Ordinary Shares (2) 6,957,623 Performance Rights
Class	(1) Ordinary Shares (2) Performance Rights
Number acquired	(1) 1,024,979 Ordinary Shares on 3/8/2022 (2)(a) 8,445,945 Performance Rights on 13/2/2023
Number disposed	(2)(b) 1,498,613 Performance Rights on 1/1/2023 (2)(c) 466,635 Performance Rights on 1/1/2022
Value/Consideration includes brokerage/gst <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	(1) \$28,699 (2)(a) Nil consideration - allotment of Performance Rights. Est. value \$228,040 (2)(b)&(c) – N/A Lapse of Performance Rights

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held after change	(1) 21,524,560 Ordinary Shares (2) 13,438,320 Performance Rights
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	(1) Acquisition under non-renounceable entitlement offer (2)(a) Allotment of Performance Rights approved by Shareholders at 2022 AGM (2)(b) and (c) - Lapse of Performance Rights

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	PainChek Limited
ABN	21 146 035 127

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Ross Harricks
Date of last notice	16 September 2021

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	N/A
Date of change	Various – see below
No. of securities held prior to change	(1) 6,449,597* Ordinary Shares (2) 396,040* Performance Rights
Class	(1) Ordinary Shares (2) Performance Rights
Number acquired	(1) Ordinary Shares a) 322,480 on 3/8/2022 b) 396,040 on 13/7/2022 (2) Performance Rights a) 675,676 on 13/2/2022
Number disposed	(2) Performance Rights b) 396,040 on 13/7/2022

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

<p>Value/Consideration includes brokerage/gst Note: If consideration is non-cash, provide details and estimated valuation</p>	<p>Acquisitions (1)(a) \$9,029 (consideration) (1)(b) Nil consideration - conversion of Performance Rights into Shares. Est. value \$10,693 (2)(a) Nil consideration - allotment of Performance Rights. Est. value \$108,243 Disposals (2)(b) Nil - Conversion of Performance Rights into Shares – refer 1(b) above.</p>
<p>No. of securities held after change</p>	<p>(1) 7,168,117 Ordinary Shares (2) 675,676 Performance Rights</p>
<p>Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	<p>(1)(a) Acquisition under non-renounceable entitlement offer (1)(b) and (2)(b) - Conversion of Performance Rights into Ordinary Shares (2)(a) Allotment of Performance Rights approved by Shareholders at 2022 AGM</p>

** There was an error on the Appendix 3Y lodged on 16/9/2021 as the numbers of Ordinary Shares and Performance Rights failed to include 206,396 Performance Rights which had been converted into Ordinary Shares on 14/7/2021.*

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<p>Detail of contract</p>	<p>N/A</p>
<p>Nature of interest</p>	<p>N/A</p>
<p>Name of registered holder (if issued securities)</p>	<p>N/A</p>
<p>Date of change</p>	<p>N/A</p>
<p>No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed</p>	<p>N/A</p>
<p>Interest acquired</p>	<p>N/A</p>
<p>Interest disposed</p>	<p>N/A</p>
<p>Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation</p>	<p>N/A</p>
<p>Interest after change</p>	<p>N/A</p>

Part 3 – +Closed period

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Were the interests in the securities or contracts detailed above traded during a ⁺ closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.